Vaksigrip, 0.5 ml 1 dose

Vaxigrippe develops specific immunity to epidemic-relevant strains of influenza virus types A and B contained in this vaccine. The immunity develops between the 2nd and 3rd week after vaccination and lasts 6 to 12 months.

Indications

Preventing the flu. Vaccination is especially indicated for people who are at higher risk of developing post-flu complications.

Composition

Active ingredient:
Influenza viruses cultured on chicken embryos, inactivated, split, three strains (15 µg hemagglutinin in an adult dose);
The strain composition of the vaccine meets the WHO recommendations for the Northern Hemisphere and the EU decision on the composition of influenza vaccines for the coming epidemic season.
Other components: buffer solution (sodium chloride, potassium chloride, sodium hydrophosphate, potassium dihydrophosphate, water for injection) – up to 0.5 ml

How to take, the dosage

Vaxigrip vaccine is given intramuscularly and deeply subcutaneously. Do not give it intravenously. The vaccine should be kept at room temperature and shaken before use.
Dosage: 0.5 ml for adults.

Interaction

Vaxigrip can be used at the same time (on the same day) as other vaccines (except BCG vaccine). In this case, the drugs are injected into different parts of the body using different syringes.

Special Instructions

Due to the seasonality of influenza, it is recommended that the vaccination be given annually in early fall.
The doctor should be informed if the patient has an immune deficiency, allergy or unusual reaction to a previous vaccination, or any treatment that coincides with or precedes the vaccination.
The vaccine should not be used if it has staining or foreign particles.
Use of this vaccine may not affect the ability to drive a car or other machinery.
The doctor should be informed of all cases of adverse reactions, including those not listed in these instructions.

Contraindications

Hypersensitivity to any of the components of the vaccine, as well as components of chicken meat or chicken eggs, neomycin, formaldehyde and octoxynol-9.
Illnesses accompanied by fever, acute manifestations of infectious disease or exacerbation of chronic disease. In these cases, vaccination should be postponed until recovery.

Side effects

Local reactions: redness, swelling, soreness, bruising, thickening at the injection site.
General reactions: elevated body temperature, malaise, chills, feeling of fatigue, headache, sweating, myalgia, arthralgia.
These reactions usually go away within 1-2 days and do not require special treatment.

In post-registration monitoring there have been rare reactions: generalized skin manifestations, including urticaria, pruritus, skin rashes, as well as neuralgia (pain along the nerve pathway), paresthesias, seizures, transient thrombocytopenia, allergic reactions (with development of shock in rare cases).
Very rarely it is noted: vasculitis with short-term involvement (in very rare cases) of the kidneys, neurological disorders (encephalomyelitis, neuritis, Guillain-Barré syndrome).